Acne Vulgaris

Dermatology·MeSH: Acne Vulgaris

Prevalence

704.9 / 100K

Incidence

360.1 / 100K/yr

12 drugs in development·9 companies·5 clinical trials

Drug Pipeline by Phase

Approved(6)

Drug	Company
amzeeq	FOAMIX PHARMACEUTICALS LTD. (FOMX)
Amzeeq	Journey Medical Corp (DERM)
CABTREO	Bausch Health Companies Inc. (BHC)
dapsone	Amneal Pharmaceuticals, Inc. (AMRX)
seysara	Paratek Pharmaceuticals, Inc. (PRTK)
tretinoin	Mylan II B.V. (MYL)

Phase 3(2)

Drug	Company
bpx-01	TREX WIND-DOWN, INC. (TMBR)
DMT310	Dermata Therapeutics Inc. (DRMA)

Preclinical(3)

Drug	Company
fcd105	FOAMIX PHARMACEUTICALS LTD. (FOMX)
fmx109	FOAMIX PHARMACEUTICALS LTD. (FOMX)
sb204	NVN Liquidation, Inc. (NOVN)

Phase 4(1)

Drug	Company
Clindamycin	Bausch Health Companies Inc. (BHC)

BioSniper tracks 12 drugs in development for Acne Vulgaris across 9 companies.

There are 5 clinical trials targeting Acne Vulgaris tracked by BioSniper.

The estimated prevalence of Acne Vulgaris is approximately 704.9 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.